Repletion of Ergothioneine in Patients With Kidney Failure
Launched by STANFORD UNIVERSITY · Jun 27, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a supplement called ergothioneine, which is a natural chemical that can be low in people with kidney failure who are on dialysis. Dialysis is a treatment that cleans the blood but can also remove some beneficial substances. The goal of this study is to find out if taking a daily ergothioneine supplement can help increase its levels in the blood of patients receiving dialysis.
To be part of this trial, participants need to be adults aged 65 to 74 who are undergoing either hemodialysis or peritoneal dialysis for kidney failure. However, people who have had a blood transfusion in the past 90 days or are taking supplements that contain ergothioneine won’t be eligible to join. While the trial is not yet recruiting participants, those who join can expect to take the supplement daily and help researchers learn more about its benefits for people with kidney issues.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • kidney failure receiving hemodialysis or peritoneal dialysis
- Exclusion Criteria:
- • blood transfusion within 90 days
- • taking supplements which contain ergothioneine
About Stanford University
Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported